第146回 WORKSHOP報告(3月11日) / 参加者73名

1.続々と参加者が集まっています。
DSCF3903

2.マテリアルの紹介 Tさん
DSCF3911

3.マテリアルの紹介 Mさん
DSCF3917
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
《 今回のworkshop 》
○workshop参加人数:67名(うち新人の方:10名)

○【前半】:Disaster reduction
○【後半】:Drug development & Approval Process:Clinical Trial
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
みなさまこんにちは、E’s club幹事のKです。
3月11日(土)開催の第146回workshopの詳細をお送りいたします。

今回は前半のマテリアルをTさん、後半のマテリアルをMさんにご作成いただきました。
前半は”Disaster reduction”、後半は”Drug development & Approval Process:Clinical Trial”というタイトルでそれぞれディスカッションを行います。

後半のリンク先には動画がありますので、事前に視聴をお願いいたします。(長さは2分24秒です。)
また資料として、前半用と後半用にそれぞれ一つずつ画像ファイルを添付しますので、こちらもご確認ください。

[今週のマテリアル]
≪FIRST HALF≫
6 years ago today, a magnitude 9.0 earthquake and following tsunami resulted in catastrophic damage to Northeast Japan.
Half a year later, I went to Tohoku area for a volunteer activity and was shocked by a terrible scene of affected area. Enormous amount of rubble were piled up mountain-high. Vast numbers of cars swept away by tsunami were still exit. Some breakwaters had been split in two. I was surprised by the power of earthquake and thought if I had been here at that time how I would have acted.
Meanwhile, casting an eye on Kansai area, there are some risks of big earthquakes and tsunamis caused by Nankai Trough or Uemachi Fault. In this workshop, I would like you to think about disaster reduction. I will give you some hypothetical situations and please imagine what you would do if you were faced with such a difficult situation.

1. While sleeping at night, you are hit by a strong earthquake. The inside of your house is a mess (but not collapsed), and the supply of electricity is stopped. What would you do at first?

2. In addition to the situation of Q1, the supply of water and gas is stopped. To survive for the next 3 days without recovery of the supply, what would you do? Do you have some stock of food or an emergency kit?

3. On your way home from your office (please set up a detailed situation by yourself), a big earthquake occurs, and public transportation is stopped. What would you do? (Please take account of the fact that the wide area of Osaka city is designated as a tsunami inundation area. See the attached map.)

4. After the situation of Q3, you somehow go back home, but your house is collapsed and unable to live in. To survive in this situation, what would you do? Have you already decided where to go?

The questions below are simple questions (not question with situation).

5. In terms of following things, what do you think is necessary or convenient? Please share your idea as many as you can come up with.
(1) things you should always carry when you go out
(2) things you should bring out soon after earthquake for survival
(3) things you should stock to live for a week in emergency situations

6. Do you take any other measures against earthquake?
ex) fixing furniture, making rules in your family, checking a route to evacuation site
If you have time, please think about cases except for earthquake.
What would you do, if you were faced with them?
・infectious disease like flu or Ebola
・super typhoon
・super cold wave
・super heat wave
・nuclear accident
・zombie virus spreading

≪LATTER HALF≫
<Agenda>
Drug development & Approval Process:Clinical Trial

<Reference 1>
YouTube “Clinical Trials – What You Need to Know”

<Reference 2>
Wikipedia “Clinical trial”
https://en.m.wikipedia.org/wiki/Clinical_trial

<Reference 3>
Japan Pharmaceutical Manufacturers Association’s homepage “Unmet medical needs”
(Below is the link to Japanese explanation 🙂 )
http://www.jpma.or.jp/about/issue/gratis/guide/guide10/10guide_06.html

<Questions>
1. What kinds of situations do you often take drugs in? (common cold, flu, hay fever, headache, stomachache, backache, hypertension, diabetes, etc.) Are you satisfied with their beneficial effect?

2. Do you use the health foods and/or supplements other than drugs?

3. Do you think drugs are essential to the medical treatment? Why?

4. ”Clinical trials” have to be conducted to develop new drugs. What kind of impression/knowledge do you have about “clinical trials”? Also, how did you know “clinical trials”?

5. Suppose that you are suffering from lifestyle-related disease (ex, diabetes, hypertension etc.).
In that case, if the doctor in charge suggested your participating in a clinical trial, would you accept the suggestion? Why? If no, do you have the courage to reject the suggestion?

6. Suppose that you are suffering from cancer and are not satisfied with the current treatment.
In that case, if the doctor in charge suggested your participating in a clinical trial, would you accept the suggestion? Why? If no, do you have the courage to reject the suggestion?

7. If a member of the family is wondering whether he/she should take part in a clinical trial as a volunteer or as a patient, would you recommend to try it? Why?

<Recent News Article>
http://www.news-medical.net/news/20170216/Clinical-trial-to-test-potential-new-drug-treatment-for-osteoarthritis.aspx

Clinical trial to test potential new drug treatment for osteoarthritis
February 16, 2017 at 9:06 AM

The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis.
Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million people*, and is the leading cause of joint pain and stiffness in older people.
As part of their research and development programme, AKL identifies promising phytochemicals, found in natural products, which are capable of being synthesized.
Trials have identified two molecules which act synergistically and have been brought together to create ‘APPA’, a patented drug.

Improved functionality
In a variety of pre-clinical animal testing trials, APPA has clearly demonstrated significant pain relief from OA, improved functionality and the slowing of cartilage destruction.
Having successfully passed preclinical toxicology studies, formal human studies can now start.
The clinical trial is due to commence shortly at the Liverpool Clinical Trials Unit (LCTU) led by rheumatologist Professor Robert Moots from the University’s Institute of Ageing and Chronic Disease.

‘Huge potential’
Professor Moots, said: “The severe pain from OA is usually managed with prescription drugs that are often not effective and that also, in many cases, induce unacceptable side effects. In many cases, major joint replacement surgery is needed to help deal with the pain. This is surely wrong.
“This drug has huge potential to provide an effective treatment for OA. A reliable and easy way to treat OA has clear potential to save large amounts of money for the NHS and greatly improve the lifestyle and health of patients.
“Working with research and development companies like AKL is crucial for the development and introduction of new treatments to benefit patients now and in future generations. We are excited to move this programme of trials forward.”

‘holy grail’
Research on how APPA affects human cells, especially activated neutrophils, is being led by Professor Steven Edwards at the University’s Institute of Integrative Biology.
Professor Edwards, said: “Neutrophils are the most abundant type of white blood cells and form an essential part of our immune system. There is now considerable evidence to show that neutrophils are activated in inflammatory diseases. They are however a “two-edged sword”: they are required to protect us from infections but their inappropriate activation can result in irreversible damage in inflammatory diseases.
“The ‘holy grail’ of anti-inflammatory targeting of neutrophils is specifically to block their tissue-damaging activities, but not compromise their ability to protect us. Work is ongoing but to date it appears that APPA does not target the host defence properties of neutrophils but does block their pro-inflammatory activities”.
David Sharples, CEO, AKL, said: “Professor Moots is leading this important clinical trial and that, in conjunction with Professor Edwards’ research on APPA’s novel modes of action, should provide the robust evidence we need to help bring this drug to market. There remains a high unmet need for an effective, well tolerated OA drug, so understandably we are very excited by APPA’s prospects”.

***********************************************************
私たちと一緒に英語コミュニケーション能力を鍛えませんか?
ご興味を持たれた方は、
入会申込フォーム
http://english-speaking-club.com/cms/?page_id=93
よりお申し込みください。お待ちしています!
***********************************************************